|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4369-4376.
Prepublished online as a Blood First Edition Paper on August 28, 2003; DOI 10.1182/blood-2003-05-1762.
Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element
James C. Mulloy,
Jorg Cammenga,
Francisco J. Berguido,
Kaida Wu,
Ping Zhou,
Raymond L. Comenzo,
Suresh Jhanwar,
Malcolm A. S. Moore, and
Stephen D. Nimer
From the Laboratory of Molecular Aspects of Hematopoiesis and the Laboratory of Developmental Hematopoiesis, Sloan-Kettering Institute, New York, NY; and the Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Hematopoiesis is a complex process involving hematopoietic stem cell (HSC) self-renewal and lineage commitment decisions that must continue throughout life. Establishing a reproducible technique that allows for the long-term ex vivo expansion of human HSCs and maintains self-renewal and multipotential differentiation will allow us to better understand these processes, and we report the ability of the leukemia-associated AML1-ETO fusion protein to establish such a system. AML1-ETO-transduced human CD34+ hematopoietic cells routinely proliferate in liquid culture for more than 7 months, remain cytokine dependent for survival and proliferation, and demonstrate self-renewal of immature cells that retain both lymphoid and myeloid potential in vitro. These cells continue to express the CD34 cell surface marker and have ongoing telomerase activity with maintenance of telomere ends, however they do not cause leukemia in nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice. Identification of the signaling pathways that are modulated by AML1-ETO and lead to the self-renewal of immature human progenitor cells may assist in identifying compounds that can efficiently expand human stem and progenitor cells ex vivo. (Blood. 2003; 102:4369-4376)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. M. Corsello, G. Roti, K. N. Ross, K. T. Chow, I. Galinsky, D. J. DeAngelo, R. M. Stone, A. L. Kung, T. R. Golub, and K. Stegmaier
Identification of AML1-ETO modulators by chemical genomics
Blood,
June 11, 2009;
113(24):
6193 - 6205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kwok, B. B. Zeisig, J. Qiu, S. Dong, and C. W. E. So
Transforming activity of AML1-ETO is independent of CBF{beta} and ETO interaction but requires formation of homo-oligomeric complexes
PNAS,
February 24, 2009;
106(8):
2853 - 2858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E.-Y. Ahn, M. Yan, O. A. Malakhova, M.-C. Lo, A. Boyapati, H. B. Ommen, R. Hines, P. Hokland, and D.-E. Zhang
Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis
PNAS,
November 4, 2008;
105(44):
17103 - 17108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Dayyani, J. Wang, J.-R. J. Yeh, E.-Y. Ahn, E. Tobey, D.-E. Zhang, I. D. Bernstein, R. T. Peterson, and D. A. Sweetser
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival
Blood,
April 15, 2008;
111(8):
4338 - 4347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhao, V. Jankovic, A. Gural, G. Huang, A. Pardanani, S. Menendez, J. Zhang, R. Dunne, A. Xiao, H. Erdjument-Bromage, et al.
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity
Genes & Dev.,
March 1, 2008;
22(5):
640 - 653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Krejci, M. Wunderlich, H. Geiger, F.-S. Chou, D. Schleimer, M. Jansen, P. R. Andreassen, and J. C. Mulloy
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death
Blood,
February 15, 2008;
111(4):
2190 - 2199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wichmann, L. Chen, M. Heinrich, D. Baus, E. Pfitzner, M. Zornig, O. G. Ottmann, and M. Grez
Targeting the Oligomerization Domain of ETO Interferes with RUNX1/ETO Oncogenic Activity in t(8;21)-Positive Leukemic Cells
Cancer Res.,
March 1, 2007;
67(5):
2280 - 2289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rizo, E. Vellenga, G. de Haan, and J. J. Schuringa
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R210 - R219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wunderlich, O. Krejci, J. Wei, and J. C. Mulloy
Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability
Blood,
September 1, 2006;
108(5):
1690 - 1697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Takeda, C. Goolsby, and N. R. Yaseen
NUP98-HOXA9 Induces Long-term Proliferation and Blocks Differentiation of Primary Human CD34+ Hematopoietic Cells.
Cancer Res.,
July 1, 2006;
66(13):
6628 - 6637.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Cammenga, S. Horn, U. Bergholz, G. Sommer, P. Besmer, W. Fiedler, and C. Stocking
Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate
Blood,
December 1, 2005;
106(12):
3958 - 3961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Stepanova and B. P. Sorrentino
A limited role for p16Ink4a and p19Arf in the loss of hematopoietic stem cells during proliferative stress
Blood,
August 1, 2005;
106(3):
827 - 832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Mulloy, V. Jankovic, M. Wunderlich, R. Delwel, J. Cammenga, O. Krejci, H. Zhao, P. J. M. Valk, B. Lowenberg, and S. D. Nimer
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion
PNAS,
March 15, 2005;
102(11):
4016 - 4021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-Y. Wang, G.-B. Zhou, T. Yin, B. Chen, J.-Y. Shi, W.-X. Liang, X.-L. Jin, J.-H. You, G. Yang, Z.-X. Shen, et al.
AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec
PNAS,
January 25, 2005;
102(4):
1104 - 1109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Licht and D. W. Sternberg
The Molecular Pathology of Acute Myeloid Leukemia
Hematology,
January 1, 2005;
2005(1):
137 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yan, S. A. Burel, L. F. Peterson, E. Kanbe, H. Iwasaki, A. Boyapati, R. Hines, K. Akashi, and D.-E. Zhang
From the Cover: Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development
PNAS,
December 7, 2004;
101(49):
17186 - 17191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Fenske, G. Pengue, V. Mathews, P. T. Hanson, S. E. Hamm, N. Riaz, and T. A. Graubert
Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice
PNAS,
October 19, 2004;
101(42):
15184 - 15189.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|